Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02419508 · ClinicalTrials.gov registry record · Phase 4
SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 290
- Enrollment target
NCT02419508: Completed Phase 4 study, sponsored by Alcon Research.
NCT02419508 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 290 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02419508, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 290 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension.
Primary Outcome
IOP (fluid pressure inside the eye) was measured using Goldmann applanation tonometry and averaged over the 09:00 AM and 11:00 AM time points. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. One eye (study eye) contributed to the analysis.
Interventions
- DRUG Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension
- DRUG Brinz/brim vehicle
- DRUG Prostaglandin analogue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2015-08-07 |
| Est. Completion | 2018-02-27 |
| Phase | Phase 4 |
What the finished NCT02419508 record still lists
NCT02419508 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 3 interventions - of which Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension is the first listed.
NCT02419508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02419508 about?
NCT02419508 is a clinical study titled "SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)". The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT02419508?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 290 participants. The study started on 2015-08-07. Estimated completion is 2018-02-27.
What interventions are being tested in trial NCT02419508?
The interventions under investigation include: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension (DRUG), Brinz/brim vehicle (DRUG), Prostaglandin analogue (DRUG).
Who is sponsoring clinical trial NCT02419508?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02419508's enrollment target sits among peer trials
290 297th of 2000 higher than 1,703 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI